NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer

Evaluation Report

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer

Contents:

1. **Appraisal Consultation Document 2 (ACD2)** as issued to consultees and commentators

2. **Consultee and commentator comments on the Appraisal Consultation Document 2** from:
   - Lilly UK
   - Royal College of Physicians

   A 'no comments' response was received from the Department of Health and the Royal College of Nursing.

3. **Second Addendum to the Evidence Review Group report prepared by Liverpool Reviews and Implementation Group**

Any information supplied to NICE which has been marked as confidential has been redacted. All personal information has also been redacted.